Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 13, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 08, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
• Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
November 09, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
July 30, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
June 01, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
March 12, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 10, 2019 11:40 ET
|
Schall Law
LOS ANGELES, May 10, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 03, 2019 20:21 ET
|
Schall Law
LOS ANGELES, May 03, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 26, 2019 09:15 ET
|
Schall Law
LOS ANGELES, April 26, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
CRBP ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. – CRBP
March 26, 2019 15:08 ET
|
Zhang Investor Law P.C.
NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Corbus Pharmaceuticals Holdings, Inc....